PCN144 IBRUTINIB TREATMENT IS ASSOCIATED WITH LOWER HEALTHCARE RESOURCE UTILIZATION AND TOTAL COST REDUCTION COMPARED TO CHEMOIMMUNOTHERAPY IN PATIENTS WITH MANTLE CELL LYMPHOMA

Autor:	D. Arthur, Reethi Iyengar, E. Malangone-Monaco, A. Sainski-Nguyen, Nick Giafis, C. Sugg, S. Gelwicks
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty business.industry Total cost Health Policy Public Health Environmental and Occupational Health medicine.disease Reduction (complexity) chemistry.chemical_compound chemistry Chemoimmunotherapy Internal medicine Ibrutinib medicine In patient Mantle cell lymphoma business Resource utilization
Zdroj:	Value in Health. 22:S83
ISSN:	1098-3015
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ad01ca7ceb14ecc78dbae8087ac5bd80 https://doi.org/10.1016/j.jval.2019.04.268 Zobrazit plný text záznamu Full Text from ScienceDirect